DOI QR코드

DOI QR Code

X-Ray Repair Cross-Complementing Group 1(XRCC1) Genetic Polymorphisms and Thyroid Carcinoma Risk: a Meta-Analysis

  • Qian, Ke (Department of Breast and Thyroid Surgery, the Second Xiangya Hospital, Central South University) ;
  • Liu, Kui-Jie (Department of General Surgery, the Second Xiangya Hospital, Central South University) ;
  • Xu, Feng (Department of Breast and Thyroid Surgery, the Second Xiangya Hospital, Central South University) ;
  • Chen, Xian-Yu (Department of Breast and Thyroid Surgery, the Second Xiangya Hospital, Central South University) ;
  • Chen, Gan-Nong (Department of Breast and Thyroid Surgery, the Second Xiangya Hospital, Central South University) ;
  • Yi, Wen-Jun (Department of Breast and Thyroid Surgery, the Second Xiangya Hospital, Central South University) ;
  • Zhou, En-Xiang (Department of Breast and Thyroid Surgery, the Second Xiangya Hospital, Central South University) ;
  • Tang, Zhong-Hua (Department of Breast and Thyroid Surgery, the Second Xiangya Hospital, Central South University)
  • Published : 2012.12.31

Abstract

A number of studies have been conducted to explore the association of XRCC1 polymorphisms with thyroid cancer risk, but the results have been inconsistent. Thus we performed the present meta-analysis to clarify this issue based on all of the evidence available to date. Relevant studies were retrieved by searching PubMed and statistical analysis conducted using Stata software. Nine studies were included in this meta-analysis (1,620 cases and 3,557 controls). There were 6 studies (932 cases and 2,270 controls) of the Arg194Trp polymorphism, 7 studies (1432 cases and 3356 controls) of the Arg280His polymorphism and 9 studies (1,620 cases and 3,557 controls) for the Arg399Gln polymorphism. No association of XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphism with thyroid cancer risk was observed in the overall analysis. However, subgroup analysis revealed: 1) an elevated risk in aa vs AA analysis (OR=2.03, 95%CI= 1.24-3.31) and recessive genetic model analysis (OR=1.93, 95%CI= 1.20-3.08) in the larger sample size trials for XRCC1 Arg194Trp polymorphism; 2) a decreased thyroid cancer risk on subgroup analysis based on ethnicity in Aa vs AA analysis (OR=0.84, 95%CI= 0.72-0.98) and in a dominant genetic model (OR=0.84, 95%CI= 0.72-0.97) in Caucasian populations for the XRCC1 Arg399Gln polymorphism; 3) a decreased thyroid cancer risk on subgroup analysis based on design type in Aa vs AA analysis (OR=0.72, 95% CI= 0.54-0.97) among the PCC trials for the Arg399Gln polymorphism. Our results suggest that the XRCC1 Arg399Gln polymorphism may be associated with decreased thyroid cancer risk among Caucasians and XRCC1 Arg194Trp may be associated with a tendency for increased thyroid cancer risk in the two larger sample size trials.

Keywords

XRCC1;Arg194Trp;Arg280His;Arg399Gln;thyroid cancer

References

  1. Monaco R, Rosal R, Dolan MA, et al (2007). Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J, 26, 541-6. https://doi.org/10.1007/s10930-007-9095-y
  2. Papadopoulou F, Efthimiou E (2009). Thyroid cancer after external or internal ionizing irradiation, Hel J Nucl Med, 12, 266-70.
  3. Ryu RA, Tae K, Min HJ, et al (2011). XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample. J Korean Med Sci, 26, 991-5. https://doi.org/10.3346/jkms.2011.26.8.991
  4. Sigurdson AJ, Land CE, Bhatti P, et al (2009). Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan. Radiat Res, 171, 77-88. https://doi.org/10.1667/RR1327.1
  5. Siraj AK, Al-Rasheed M, Ibrahim M, et al (2008). RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. J Endocrinol Invest, 31, 893-9. https://doi.org/10.1007/BF03346438
  6. Tumer TB, Yilmaz D, Tanrikut C, et al (2010). DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia. Leuk Res, 34, 1275-81. https://doi.org/10.1016/j.leukres.2010.02.035
  7. Vodicka P, Stetina R, Polakova V, et al (2007). Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis, 28, 657-64.
  8. Wang L, Yin F, Xu X, Hu X, Zhao D (2012). X-ray repair crosscomplementing group 1 (XRCC1) genetic polymorphisms and risk of childhood acute lymphoblastic leukemia: a metaanalysis. PLoS One, 7, e34897. https://doi.org/10.1371/journal.pone.0034897
  9. Xing D, Qi J, Miao X, et al (2002) Polymorphisms of DNA repair Genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer, 100, 600-5. https://doi.org/10.1002/ijc.10528
  10. Yan L, Yanan D, Donglan S, et al. (2009) Polymorphisms of XRCC1 gene and risk of gastric cardiac adenocarcinoma. Dis Esophagus, 22, 396-401. https://doi.org/10.1111/j.1442-2050.2008.00912.x
  11. Zhu QX, Bian JC, Shen Q, et al (2004). Genetic polymorphisms in X-ray repair cross-complementing gene 1 and susceptibility to papillary thyroid carcinoma. Zhonghua Liu Xing Bing Xue Za Zhi, 25, 702-5.
  12. Chou WC, Wang HC, Wong FH, et al (2008). Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J, 27, 3140-50. https://doi.org/10.1038/emboj.2008.229
  13. Dai L, Duan F, Wang P, et al (2012). XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 casecontrol studies. Mol Biol Rep, 39, 9535-47. https://doi.org/10.1007/s11033-012-1818-2
  14. Egger M, Davey SG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  15. Fard-Esfahani P, Fard-Esfahani A, Fayaz S, et al (2011). Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms in X-ray repair cross-complementing group 1 gene and risk of differentiated thyroid carcinoma in Iran. Iran Biomed J, 15, 73-8.
  16. Garcia-Quispes WA, Perez-Machado G, Akdi A, et al (2011). Association studies of OGG1, XRCC1, XRCC2 and XRCC3 polymorphisms with differentiated thyroid cancer. Mutat Res, 709-710, 67-72. https://doi.org/10.1016/j.mrfmmm.2011.03.003
  17. Gilfillan CP (2010). Review of the genetics of thyroid tumours: diagnostic and prognostic implications. ANZ J Surg, 80 33-40. https://doi.org/10.1111/j.1445-2197.2009.05173.x
  18. Gudmundsson J, Sulem P, Gudbjartsson DF, et al (2012). Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet, 44, 319-22. https://doi.org/10.1038/ng.1046
  19. Hoeijmakers HJ (2001). Genome maintenance mechanisms for prevaenting cancer. Nature, 411, 366-74. https://doi.org/10.1038/35077232
  20. Ho T, Li G, Lu J, et al (2009). Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid, 19, 129-35. https://doi.org/10.1089/thy.2008.0153
  21. Huang Y, Li L, Yu L (2009). XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a metaanalysis. Mutagenesis, 24, 331-9. https://doi.org/10.1093/mutage/gep013
  22. Hu JJ, Smith TR, Miller MS, et al (2001). Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis, 22, 917-22. https://doi.org/10.1093/carcin/22.6.917
  23. Jendrzejewski J, He H, Radomska HS, et al (2012). The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci, 109, 8646-51.a https://doi.org/10.1073/pnas.1205654109
  24. Mani RS, Fanta M, Karimi-Busheri F, et al (2007). XRCC1 stimulates polynucleotide kinase by enhancing its damage discrimination and displacement from DNA repair intermediates. J Biol Chem, 282, 28004-13. https://doi.org/10.1074/jbc.M704867200
  25. Mani RS, Karimi-Busheri F, Fanta M, et al (2004). Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA. Biochemistry, 43, 16505-14. https://doi.org/10.1021/bi048615m
  26. Marsin S, Vidal AE, Sossou M, et al (2003). Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1, J Biol Chem, 278, 44068-74. https://doi.org/10.1074/jbc.M306160200
  27. Matullo G, Dunning AM, Guarrera S, et al (2006). DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis, 27, 997-1007. https://doi.org/10.1093/carcin/bgi280
  28. Ming M, He YY (2012). PTEN in DNA damage repair. Cancer Lett, 319, 125-9. https://doi.org/10.1016/j.canlet.2012.01.003
  29. Akulevich NM, Saenko VA, Rogounovitch TI, et al (2009). Polymorphisms of DNA damage response genes in radiationrelated and sporadic papillary thyroid carcinoma. Endocr Relat Cancer, 16, 491-503. https://doi.org/10.1677/ERC-08-0336
  30. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS (2011). Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid, 21, 125-34. https://doi.org/10.1089/thy.2010.0021
  31. Chen B, Zhou Y, Yang P, Wu XT (2012). Polymorphisms of XRCC1 and gastric cancer susceptibility: a meta-analysis. Mol Biol Rep, 39, 1305-13. https://doi.org/10.1007/s11033-011-0863-6
  32. Chiang FY, Wu CW, Hsiao PJ, et al (2008). Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. Clin Cancer Res, 14, 5919-24. https://doi.org/10.1158/1078-0432.CCR-08-0906

Cited by

  1. Association between the XRCC1 Polymorphisms and Thyroid Cancer Risk: A Meta-Analysis from Case-Control Studies vol.9, pp.9, 2014, https://doi.org/10.1371/journal.pone.0087764
  2. Molecular genetics of thyroid cancer vol.98, pp.1469-5073, 2016, https://doi.org/10.1017/S0016672316000057